Grupo Somar invests US$11 million in the Valley of Mexico

Grupo Somar, a Mexican pharmaceutical laboratory conglomerate, announced a total investment of US$11 million to expand its production and research capacity in the Mexico City Metropolitan Area (ZMVM).

This investment package is divided into two main areas: US$10.7 million for infrastructure and equipment, and US$1.2 million for clinical research.

The investment in infrastructure will focus on three specific projects. In Chalco, State of Mexico, a new plant will be built for two production lines of effervescent products, positioning Somar as one of the only players with three plants of this type in the country.

In Naucalpan, State of Mexico, a new soft gelatin line will be installed to increase existing production capacity. Additionally, the Chalco plant will undergo expansions and improvements to its oral solids production equipment.

In terms of research, the company will allocate US$1.2 million to conduct more than 100 bioequivalence and phase IV studies during 2025 and 2026. These studies will be carried out mainly through local CROs (Contract Research Organizations), which will strengthen the innovation ecosystem in the region.

The investment will generate 200 new direct jobs and more than 600 indirect jobs.

The investment is part of Plan Mexico, the federal strategy designed to direct strategic investments to regions according to their specific capabilities, said Laura González, Secretary of Economic Development for the State of Mexico.